Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)

The summary for the Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required): Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (CSC), have been found to produce a range of positive clinical and functional outcomes. However, the timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based services, and effective engagement in CSC are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning grant applications that (1) identify a baseline rate of DUP in community settings that include CSC programs; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP.
Federal Grant Title: Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-18-232
Type of Funding: Grant
CFDA Numbers: 93.242
CFDA Descriptions: Information not provided
Current Application Deadline: March 19th, 2019
Original Application Deadline: March 19th, 2019
Posted Date: November 21st, 2017
Creation Date: November 21st, 2017
Archive Date: April 24th, 2019
Total Program Funding:
Maximum Federal Grant Award: $225,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: November 21st, 2017
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-18-232.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
Lethal Means Safety Suicide Prevention Research in Healthcare and Community Settings (R34 ...
Strategies to Improve Health Outcomes and Advance Health Equity in Rural Populations (R01 ...
Consortium for Palliative Care Research Across the Lifespan (U54 Clinical Trial Optional)
Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com